Artificial Intelligence: Clinical Stage Pharmatech Startup Exscientia Acquires AI-Powered Allcyte

Allcyte’s Pharmascopy platform interrogates drug action in primary human tissues with automated high content microscopy and AI-powered single-cell image analysis.

Exscientia, which uses AI to design and create drug candidate molecules satisfying complex therapeutic requirements with revolutionary efficiency, has acquired Allcyte, the Austrian company that uses AI for cancer screening. Exscientia will pay 50 million euros ($60.6 million) in a combination of cash and shares for the acquisition. (Fortune)

Last month Exscientia announced that its joint research with Sumitomo Dainippon Pharma Co., Ltd. (TYO: 4506) had resulted in the creation of the molecule DSP-0038, a dual-targeted 5-HT1A agonist and 5-HT2A antagonist to be assessed for treatment of Alzheimer’s disease psychosis.

Sumitomo will now initiate a Phase 1 clinical study of DSP-0038 in the United States.

The rationale for acquiring Allcyte

Allcyte’s Pharmascopy is the first-ever functional precision oncology platform that has demonstrated the ability to prioritize highly effective drugs in a prospective clinical study.

Pharmascopy scans the efficacy of a wide range of drugs on live tumor samples taken from a patient. It does this using high-speed, robotic laboratory equipment and then applies computer vision to analyze how the patient’s cells are responding to each drug.

The procedure results in identifying the potentially most effective drug treatment for the patient’s cancer affliction. Allcyte is therefore said to be a pioneer in personalized medicine AI.

Exscientia and Allcyte previously collaborated on a study to assess the performance of an anti-cancer immunotherapy drug Exscentia is developing in collaboration with German pharmaceutical company Evotec.

Vision of patient-first AI

“Allcyte is able to demonstrate what therapy actually works in the individual patient with the most disease-relevant screening platform we have seen.”, said Andrew Hopkins, Exscientia’s CEO.  “Combining Allcyte’s platform with Exscientia’s technologies can redefine how drugs are developed, enabling integrated discovery and patient selection. Allcyte has assembled an outstanding team in Vienna and the integration of the two platforms truly allows us to build our vision of patient-first AI.”

Related Story: A Molecule For Alzheimer’s Created By Exscientia’s AI Enters Clinical Trials

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Latest Alternative Investment News
FinTech: New Players In BNPL, And Down Under, Stocks Are Hammered
November 29, 2021     FinTech, News

Afterpay enters subscriptions market, Monzo’s Pay Later, Suncorp hops onto the BNPL bandwagon, and BNPL stocks get clobbered in Australia
Digital Assets: Grayscale’s Report Paints The Metaverse As The Next Emerging Market Investment Frontier
November 29, 2021     Digital Assets, News

A report issued by Grayscale Research, a unit of Grayscale Investments, the largest digital asset manager in the world, describes the Metaverse as a potential market opportunity worth over $1…
Artificial Intelligence: UNESCO Member States Adopt The First Ever Global Agreement On The Ethics Of Artificial Intelligence
November 29, 2021     Artificial Intelligence, News

The first ever global standard on the ethics of artificial intelligence (AI) was adopted by the member states of UNESCO at its General Conference on Tuesday. Audrey Azoulay, director-general of…
Venture Capital: Indian Fantasy Gaming Group Dream Sports Raises $840M
November 29, 2021     Latest News, News, Venture Capital

Dream Sports announced last week its raise of $840 million from investors led by Falcon Edge, DST Global, D1 Capital, Redbird Capital and Tiger Global, with the transaction valuing the…